Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and PipelineBusiness Wire • 07/25/24
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024Business Wire • 07/24/24
AHF Press Conference: Advocates Demand Gilead to Put Lives Before Profits at AIDS 2024Business Wire • 07/22/24
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 NamesInvestorPlace • 07/19/24
Want $3,000 In Passive Income? Invest $51,000 in These 3 High-Yield Dividend PlaysThe Motley Fool • 07/17/24
Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024Business Wire • 07/16/24
Gilead Sciences: Strategic Gains From Lenacapavir And Trodelvy Justify A Buy RatingSeeking Alpha • 06/24/24
GILD Stock Today: Why A Broken Wing Butterfly Might Make Money In Gilead Sciences StockInvestors Business Daily • 06/21/24